ABOUT PCI BIOTECH
PCI Biotech (OSE: PCIB) is a biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange. The company develops novel therapies and new technologies through its proprietary photochemical internalisation (PCI) platform technology originating from world-leading research at the Oslo University Hospital – the Norwegian Radium Hospital. The PCI technology works by inducing light-triggered endosomal release, which may unlock the potential of a wide array of modalities. The company is applying the technology platform in distinct programmes:
This programme utilises the proven capability of the PCI technology for intracellular delivery of nucleic acids. The technology can be used for most types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids to viral vectors. The development of the programme is currently focussed on selected applications within dermatology and bioprocessing that are well suited to the specific strengths of the PCI technology.
The programme aims to enhance immunotherapy in cancer by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. It has been demonstrated excellent efficacy with protein- and peptide-based vaccines in preclinical experiments, with particularly strong cytotoxic (CD8) T-cell immune responses, which are crucial in cancer immunotherapy. The beneficial immune characteristics have been successfully verified in humans through a Phase I study with healthy subjects.
PCI Biotech is a member of Oslo Cancer Cluster, an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines. Oslo Cancer Cluster is a national non-profit member organisation for Norwegian and international companies, research and financial institutions, university hospitals and organisations – all working in the cancer field.
Read more about Oslo Cancer Cluster here: